Compare Moody's Corporation (MCO) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moody's Corporation vs State Street SPDR S&P Biotech ETF — how do they compare? Moody's Corporation trades at $478.67 (market cap $82.52B), while State Street SPDR S&P Biotech ETF trades at $159.17. The key difference: Moody's Corporation pays a 0.86% dividend while State Street SPDR S&P Biotech ETF pays none, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Moody's Corporation nearer its low. Which is the better fit depends on your goals.
| MCO | XBI | |
|---|---|---|
Market Cap | $82.52B | — |
Sector | Financials | Broad Market / Factor |
52-Week High | $539.61 | $164.28 |
52-Week Low | $412.23 | $86.92 |
Enterprise Value | $88.54B | — |
Dividend Yield | 0.86% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moody's Corporation (MCO) trades at $477.00, down 0.24% on the day, with strong fundamentals including 80.15% ROE and 34.25% net margin. The stock shows bearish technical signals but maintains robust earnings momentum with three consecutive quarterly beats. Revenue growth accelerated to $7.72 billion in 2025, while analyst consensus remains bullish with a $561.88 price target representing 18% upside potential.
MCO presents a compelling growth story with premium valuation metrics (P/E 30.23) justified by consistent earnings outperformance and dominant market position. Key risks include sensitivity to debt issuance cycles and elevated valuation multiples. The combination of strong profitability, analyst support, and dividend payments supports a positive long-term outlook despite near-term technical weakness.
XBI trades at $158.81, up 0.49% today, with a bullish technical signal supported by moving averages. The ETF shows strong momentum with a 17% monthly gain and 75% annual return, driven by biotech sector strength. Analyst coverage is limited to one hold rating, while recent news highlights institutional buying interest and positive sector developments including M&A activity and drug trial successes.
The outlook remains positive given biotech's breakout from multi-year bear markets, though elevated volatility and policy risks persist. Key opportunities include AI-driven drug discovery and sustained M&A momentum, while risks involve sector-specific volatility and regulatory uncertainty. The ETF's equal-weight approach provides diversified exposure to biotech innovation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Moody's Corporation
Moody's, along with S&P Ratings, is a leading provider of credit ratings on fixed income securities. Moody's ratings segment, known as Moody's Investors Service or MIS, includes corporates, structured finance, financial institutions, and public finance ratings. MIS represents a majority of the firm's revenue and profits. Moody's other segment is Moody's Analytics and consists of Research, Data, and Analytics or RD&A and Enterprise Risk Solutions or ERS. RD&A's products include credit research, quantitative credit scores, economic research, business intelligence, know your customer (KYC) tools, commercial real estate data and analytical tools, and training services. ERS includes risk management software solutions to financial institutions.
Read more on MCO →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
